Kilitch Drugs sets Aug 27 for 34th AGM; book closure begins Aug 20

1 min read     Updated on 01 Aug 2026, 07:45 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Kilitch Drugs (India) Limited will hold its 34th Annual General Meeting on August 27, 2026, via video conferencing. The book closure for the register of members runs from August 20 to August 27, 2026. Shareholders must hold shares as of August 20, 2026, to exercise voting rights electronically through MUFG Intime India Private Limited.

powered bylight_fuzz_icon
47139299

*this image is generated using AI for illustrative purposes only.

Kilitch Drugs (India) Limited has scheduled its 34th Annual General Meeting (AGM) for Thursday, August 27, 2026, to be conducted through Video Conferencing and other Audio Visual Means. The company will close its Register of Members and Share Transfer Register from Thursday, August 20, 2026, to Thursday, August 27, 2026, both days inclusive, to determine shareholder eligibility for the notice and voting rights.

The cut-off date for determining members eligible to receive the Notice of AGM and Annual Report was Friday, July 24, 2026. For the purpose of exercising voting rights at the AGM, the record date is fixed as Thursday, August 20, 2026. Shareholders holding equity shares as of this date are entitled to vote on the items of business transacted during the meeting.

Voting Mechanism and Compliance

In compliance with Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Kilitch Drugs will provide members the facility to exercise their votes electronically. The company has engaged MUFG Intime India Private Limited, its Share Transfer Agents, to facilitate e-voting through their dedicated platform.

The announcement was made pursuant to Regulation 42(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The notice was issued by Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, and submitted to the BSE Limited and National Stock Exchange of India Ltd.

Key Dates and Details

Event Date Details
Cut-off for AGM Notice Eligibility July 24, 2026 Friday
Book Closure Start August 20, 2026 Thursday
Book Closure End August 27, 2026 Thursday
Record Date for Voting Rights August 20, 2026 Thursday
34th Annual General Meeting August 27, 2026 Thursday, 9:00 a.m. via Video Conferencing

The AGM is scheduled to commence at 9:00 a.m. on August 27, 2026. Shareholders are advised to ensure their holdings are reflected in the register by the record date to participate in the electronic voting process.

Historical Stock Returns for Kilitch Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
-0.62%+8.72%-2.74%-39.67%-57.33%-13.77%

What specific agenda items or strategic resolutions are expected to be tabled at Kilitch Drugs' 34th AGM?

How might the outcomes of the AGM voting influence Kilitch Drugs' future dividend policy or capital allocation strategy?

Are there any anticipated changes in board composition or executive leadership to be discussed during the meeting?

Kilitch Drugs posts 4% PAT rise in FY26, seeks ₹2 cr exec pay

2 min read     Updated on 01 Aug 2026, 07:28 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Kilitch Drugs posted a 4% rise in consolidated PAT to ₹32.39.96 lakh in FY26, supported by increased export revenue. The firm is convening its AGM to approve ₹2 crore in executive incentives and ratify cost auditor fees.

powered bylight_fuzz_icon
46793006

*this image is generated using AI for illustrative purposes only.

Kilitch Drugs (India) Limited reported a consolidated net profit of ₹32.39.96 lakh for the fiscal year ended March 31, 2026 (FY26), an increase from ₹31.15.69 lakh in FY25, driven by robust export sales and improved operational efficiencies. The pharmaceutical manufacturer has scheduled its 34th Annual General Meeting (AGM) for August 27, 2026, to seek shareholder approval for performance-linked incentives totaling ₹2 crore for its executive directors and to ratify the remuneration of its cost auditors.

The Board of Directors approved these resolutions during a meeting held on July 28, 2026, in compliance with Regulation 30 and Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has closed its Register of Members and Share Transfer Books from August 20, 2026, to August 27, 2026, both days inclusive, to determine shareholders entitled to vote. This closure is mandated under Regulation 42 of the SEBI Listing Regulations.

Key Financial Performance

Kilitch Drugs achieved a consolidated revenue from operations of ₹23,547.49 lakh in FY26, compared to ₹19,831.85 lakh in the previous year. The growth was primarily fueled by export sales, which stood at ₹13,281.46 lakh, representing a significant portion of the total income. Standalone revenue from operations also rose to ₹18,857.43 lakh from ₹18,158.73 lakh.

Metric FY26 (₹ Lakh) FY25 (₹ Lakh)
Consolidated Revenue 23,547.49 19,831.85
Consolidated PAT 3,239.96 3,115.69
Standalone Revenue 18,857.43 18,158.73
Standalone PAT 3,239.96 3,115.69

The company’s EBITDA for the consolidated entity was ₹4,628.47 lakh. Management highlighted that the new greenfield manufacturing facility at Pen, Maharashtra, is now operational in phases, strengthening manufacturing capabilities and supply chain resilience.

Executive Compensation and AGM Agenda

The primary special business involves approving Performance-Linked Incentives (PLI) for three executive directors, based on the recommendation of the Nomination and Remuneration Committee. The Board cited their pivotal role in business growth and brand development as justification for the payouts.

Executive Director Designation PLI Amount (₹)
Mukund Mehta Managing Director 50,00,000
Bhavin Mehta Wholetime Director 1,00,00,000
Mira Mehta Managing Director 50,00,000

Additionally, shareholders will ratify the remuneration of M/s Arvind Kumar & Co., Cost Accountants (Firm Registration No. 000646), for the financial year 2026-27. The approved fee is ₹60,000 excluding taxes. The firm’s partner, Mr. Arvind Kumar (Membership No. 37904), has no relationship with the company’s directors or key managerial personnel.

Voting and Compliance Details

The remote e-voting facility will be active from Monday, August 24, 2026, at 9:00 am IST, until Wednesday, August 26, 2026, at 5:00 pm IST. Only members recorded in the Register of Members or Register of Beneficial Owners as of the cut-off date, August 20, 2026, are eligible to vote. Mr. Deep Shukla of Deep Shukla & Associates, Company Secretaries, has been appointed as the Scrutinizer to oversee the voting process and declare results within 48 hours of the meeting's conclusion.

Shareholders attending via video conferencing must register through the InstaMeet platform. Those who have already cast remote e-votes may attend but cannot vote again during the live session. The company emphasizes that all transfers of physical securities must be in demat mode, as per SEBI circulars effective from January 25, 2022.

Historical Stock Returns for Kilitch Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
-0.62%+8.72%-2.74%-39.67%-57.33%-13.77%

How will the phased operationalization of the new Pen manufacturing facility impact Kilitch Drugs' production capacity and cost efficiency in FY27?

What is the strategic rationale behind the significant disparity in Performance-Linked Incentives between Bhavin Mehta and the other executive directors?

Can the current growth trajectory driven by export sales be sustained given potential regulatory changes or currency fluctuations in key international markets?

More News on Kilitch Drugs

1 Year Returns:-57.33%